Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors
暂无分享,去创建一个
David C. Smith | A. Chinnaiyan | Xuhong Cao | D. Robinson | D. Hayes | E. Stoffel | C. Kumar-Sinha | S. Schuetze | A. Alva | Pankaj Vats | M. Talpaz | S. Camelo-Piragua | F. Worden | Yi-Mi Wu | R. Lonigro | Rui Wang | L. Kunju | M. Zalupski | Yu Ning | A. Udager | R. Chugh | A. Schott | E. Cobain | V. Sahai | Michelle F. Jacobs | Megan E V Caram | M. Cieslik | Erica Rabban | David Lucas | Janice Bell | David R. Lucas | M. Caram | Chandan Kumar-Sinha | Megan E. V. Caram
[1] David J. Sims,et al. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Alex H. Wagner,et al. A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer , 2020, Nature Genetics.
[3] L. Diaz,et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Ying Cheng,et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.
[5] J Jack Lee,et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial , 2019, Nature Medicine.
[6] F. Nielsen,et al. Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials , 2018, Clinical Cancer Research.
[7] N. Schultz,et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] Edward S. Kim,et al. Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. , 2018, JCO precision oncology.
[9] Ying Cheng,et al. Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[10] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[11] Robert J. Lonigro,et al. Integrative Clinical Genomics of Metastatic Cancer , 2017, Nature.
[12] Marie-Cécile Le Deley,et al. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. , 2017, Cancer discovery.
[13] K. Hess,et al. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. , 2017, JCO precision oncology.
[14] Moriah H Nissan,et al. OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.
[15] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[16] Marilyn M. Li,et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.
[17] Marian Harris,et al. Institutional implementation of clinical tumor profiling on an unselected cancer population. , 2016, JCI insight.
[18] Milan Radovich,et al. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers , 2016, Oncotarget.
[19] R. Yelensky,et al. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. , 2016, Cancer research.
[20] S. Lippman,et al. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience , 2016, Molecular Cancer Therapeutics.
[21] Nicolas Servant,et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.
[22] A. Chen,et al. An overview of the NCI precision medicine trials-NCI MATCH and MPACT. , 2015, Chinese clinical oncology.
[23] Vladimir Vacic,et al. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. , 2015, JAMA oncology.
[24] Funda Meric-Bernstam,et al. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] R. Kurzrock,et al. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients , 2015, Molecular Cancer Therapeutics.
[26] Razelle Kurzrock,et al. Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses , 2014, Clinical Cancer Research.
[27] J. Doroshow,et al. Molecular analysis for therapy choice: NCI MATCH. , 2014, Seminars in oncology.
[28] Niels Richard Hansen,et al. Modeling tissue contamination to improve molecular identification of the primary tumor site of metastases , 2014, Bioinform..
[29] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[30] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[31] L. Moja,et al. Trastuzumab containing regimens for early breast cancer. , 2012, The Cochrane database of systematic reviews.
[32] Lee T. Sam,et al. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.
[33] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.